Health-related quality of life among patients with metastatic melanoma: Results from an international phase 2 multicenter study

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 54-62

  Robinson Jr , Donald W ^a   Cormier, Janice N ^c   Zhao, Ning ^a   Uhlar, Clarissa M ^b   Revicki, Dennis A ^d   Cella, David ^e  

^a Janssen Global Services   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

epidemiology; health related quality of life; intetumumab; melanoma; psychometric; symptom

Indexed keywords

DACARBAZINE; HEMOGLOBIN; INTETUMUMAB; LACTATE DEHYDROGENASE; PLACEBO;

ADULT; APPETITE; ARTICLE; BRIEF PAIN INVENTORY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; DESCRIPTIVE RESEARCH; FATIGUE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PAIN; PAIN MEASUREMENT; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84855783790     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834d3da0     Document Type: Article

References (22)

1. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6):vi51-vi58.
2. Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003; 39:1577-1585. (Pubitemid 36829198)
3. Cohen L, Parker PA, Sterner J, De Moor C. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumourderived vaccine. Melanoma Res 2002; 12:505-511. (Pubitemid 35264728)
4. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008; 112:2249-2257. (Pubitemid 351628636)
5. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 2006; 106:494-504. (Pubitemid 43157611)
6. Greene FL, Page DL, editors. American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer; 2002.
7. O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al. A randomised, phase II study of intetumumab, an anti-av-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011; 105:346-352.
8. Cormier JN, Davidson L, Xing Y,Webster K, Cella D. Measuring quality of life in patients with melanoma: Development of the FACT-melanoma subscale. J Support Oncol 2005; 3:139-145. (Pubitemid 40439757)
9. Cella D, editor. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system, Version 4.1 edn. Evanston: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 2004.
10. Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain 2003; 4:2-21. (Pubitemid 36222740)
11. Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, et al. The Brief Pain Inventory and its "pain at its worst in the last 24 hours'' item: Clinical trial endpoint considerations. Pain Med 2009; 11:337-346.
12. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer 1997; 33:20-28. (Pubitemid 27099561)
13. Hahn EA,Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions. Stat Med 1998; 17:547-559. (Pubitemid 28118927)
14. Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, Gibson D, et al.; for the Medical Research Council Lung Cancer Working Party and the CHART Steering Committee. Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. Eur J Cancer 1998; 34:49-57. (Pubitemid 28123380)
15. Hays RD, Revicki DA. Reliability and validity (including responsiveness). In: Fayers PM, Hays RD, editors. Assessing quality of life in clinical trials: Methods and practice. 2nd ed. New York: Oxford University Press; 2005. pp. 25-40.
16. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166. (Pubitemid 30036349)
17. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value Health 2009; 12:1144-1150.
18. Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007; 10:1338-1346. (Pubitemid 350308638)
19. Collett D. Types of time-dependent variables. Modelling survival data in medical research. 2nd ed. Boca Raton, FL: Chapman & Hall; 2003. pp. 252-270.
20. Wong R,Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;CD002068.
21. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Eval Health Prof 2005; 28:172-191. (Pubitemid 40628906)
22. Chang CH, Cella D, Clarke S, Heinemann AW, Von Roenn JH, Harvey R. Should symptoms be scaled for intensity, frequency, or both? Palliat Support Care 2003; 1:51-60.